Vigencell reported positive top‑line results from a Phase II study of VT‑EBV‑N, an antigen‑specific killer T‑cell therapy targeting NK/T‑cell lymphoma, and plans to seek conditional approval in South Korea. The company said the data support its manufacturing and regulatory dossier to request expedited local authorization. VT‑EBV‑N is positioned as a targeted cellular approach for an aggressive lymphoma subtype with few options; Vigencell will engage Korean regulators to determine next steps toward conditional marketing while preparing for broader development.